Levodopa-carbidopa intestinal gel vs Rytary (IPX066)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Levodopa-carbidopa intestinal gel · Duopa

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Weak signal

NCT00335153 · Phase 3 · completed

This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.

Reported efficacy

Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66) (met)

Result source: NCT00357994

Rytary (IPX066)

Marketed by Amneal Pharmaceuticals

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT00974974 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).

Reported efficacy

Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)

Result source: NCT00974974

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLevodopa-carbidopa intestinal gelRytary (IPX066)
OFF time, change-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381
—Not reported
ON time without troublesome dyskinesia, change4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381
—Not reported
UPDRS Part III, change-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387
21.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791
MDS-UPDRS Part II, change—Not posted · NCT01960842—Not reported

OFF time, change

Levodopa-carbidopa intestinal gel
-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381
Rytary (IPX066)
—Not reported

ON time without troublesome dyskinesia, change

Levodopa-carbidopa intestinal gel
4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381
Rytary (IPX066)
—Not reported

UPDRS Part III, change

Levodopa-carbidopa intestinal gel
-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387
Rytary (IPX066)
21.6 vs 25.5vs IR CD-LDwk 0 · n 27NCT00869791

MDS-UPDRS Part II, change

Levodopa-carbidopa intestinal gel
—Not posted · NCT01960842
Rytary (IPX066)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Levodopa-carbidopa intestinal gel: 4 of 4 rows · Rytary (IPX066): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLevodopa-carbidopa intestinal gelRytary (IPX066)
Dropout rate
8.5%a
NCT00335153 · Phase 3
show 13 more results
5.4%
NCT00357994 · Phase 3
43.2%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
27.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
33.3%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
15.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
44.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
10.7%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
9.7%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
5.4%
NCT00660387 · Phase 3 · registry result, not featured evidence
37.5%
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
—b
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
24.5%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
20.2%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
17.2%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
8.1%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.4%a
NCT00335153 · Phase 3
show 13 more results
2.7%
NCT00357994 · Phase 3
18.9%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
22.7%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
11.1%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
4.4%
NCT02549092 · Phase 3 · registry result, not featured evidence
32.1%
NCT00660673 · Phase 3 · registry result, not featured evidence
3.6%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
3.2%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
2.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
—
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
—b
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
15.3%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
14.4%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
5.7%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
—Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
—Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
—
NCT01130493 · Phase 3 · registry result, not featured evidence
2.6%
NCT01096186 · Phase 3 · registry result, not featured evidence
—
NCT00869791 · Phase 2 · registry result, not featured evidence
Serious AEs
30.5%a
NCT00335153 · Phase 3
show 13 more results
13.5%
NCT00357994 · Phase 3
66.7%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
77.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
77.8%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
20.9%
NCT02549092 · Phase 3 · registry result, not featured evidence
60.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
20.5%
NCT01736176 · Phase 3 · registry result, not featured evidence
12.9%
NCT01960842 · Phase 3 · registry result, not featured evidence
22.6%
NCT00360568 · Phase 3 · registry result, not featured evidence
13.5%
NCT00660387 · Phase 3 · registry result, not featured evidence
16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
0%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
5.5%b
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
2%390 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.8%245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
4.6%145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
2.3%Part 1: Conversion
NCT01411137 · Phase 3 · registry result, not featured evidence
15.6%Part 2: Open-Label Extension 1
NCT01411137 · Phase 3 · registry result, not featured evidence
25%Part 3: Open-Label Extension 2
NCT01411137 · Phase 3 · registry result, not featured evidence
1.1%
NCT01130493 · Phase 3 · registry result, not featured evidence
7%
NCT01096186 · Phase 3 · registry result, not featured evidence
0%
NCT00869791 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
complication of device insertion 28.8%
abdominal pain 26%
insomnia 18.9%
NCT00335153 · Phase 3
show 13 more results
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00357994 · Phase 3
constipation 22.2%
depression 19.4%
device dislocation 19.4%
NCT00141518 · Phase 4 · registry result, not featured evidence
device dislocation 36.4%
excessive granulation tissue 31.8%
device related infection 27.3%
NCT00141518 · Phase 4 · registry result, not featured evidence
blood homocysteine increased 33.3%
device dislocation 27.8%
constipation 22.2%
NCT00141518 · Phase 4 · registry result, not featured evidence
stoma site pain 14%
abdominal pain 11.6%
stoma site infection 11.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
vitamin b6 decreased 27.1%
blood homocysteine increased 22.5%
postoperative wound infection 21%
NCT00660673 · Phase 3 · registry result, not featured evidence
fall 21.4%
procedural pain 10.7%
abdominal pain 7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
procedural pain 33.3%
stoma site infection 28.2%
stoma site pain 23.1%
NCT01736176 · Phase 3 · registry result, not featured evidence
incision site pain 41.9%
excessive granulation tissue 32.3%
constipation 19.4%
NCT01960842 · Phase 3 · registry result, not featured evidence
incision site erythema 29%
fall 21%
vitamin b6 decreased 21%
NCT00360568 · Phase 3 · registry result, not featured evidence
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
dyskinesia 33.3%
fall 33.3%
anaemia 16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
cold sweat 9.1%
diarrhoea 9.1%
headache 9.1%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
b
insomnia 3.5%
fall 3%
nausea 3%
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 9 more results
390 mg LD
nausea 20.4% (placebo 8.7%)
headache 17.3% (placebo 10.9%)
dizziness 12.2% (placebo 5.4%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
245 mg LD
dizziness 19.2% (placebo 5.4%)
nausea 19.2% (placebo 8.7%)
headache 12.5% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
145 mg LD
nausea 13.8% (placebo 8.7%)
dizziness 9.2% (placebo 5.4%)
headache 6.9% (placebo 10.9%)
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
nausea 11.6%
dyskinesia 7%
fall 7%
NCT01411137 · Phase 3 · registry result, not featured evidence
upper respiratory infection 15.6%
anxiety 6.3%
fall 6.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
fall 16.7%
orthostatic hypotension 16.7%
anxiety 8.3%
NCT01411137 · Phase 3 · registry result, not featured evidence
dyskinesia 4.5%
confusional state 3.4%
insomnia 3.4%
NCT01130493 · Phase 3 · registry result, not featured evidence
insomnia 5.8%
dyskinesia 5.5%
fall 5.3%
NCT01096186 · Phase 3 · registry result, not featured evidence
anxiety 3.7%
fatigue 3.7%
feeling of warth in abdomen 3.7%
NCT00869791 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 13 of these studies.
  2. bPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Levodopa-carbidopa intestinal gel

AIMS Total -1.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint; n=317
NCT00335153 · Phase 3
OFF Time -4.44 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-1.3 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time With Td -0.36 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.24 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time Without Td 3.86 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
1.54 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
CGI-I 2.1 score @ 54wk
absolute value · score
No placebo or comparator arm
CGI-I at Endpoint
NCT00335153 · Phase 3
UPDRS I 0 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS II -4.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS Part III -7.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
0.6 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
UPDRS -11.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS IV -3.5 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
PDQ-39 Summary Index -6.9 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.7 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
PDQ-39 Mobility -11.2 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-2.5 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence

+ 332 further endpoints in the CSV export.

Rytary (IPX066)

Off" Time 23.82% (n=201) vs 29.79% (n=192) IR CD-LD @ 22wk
absolute value · percentage points
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
Off" Time 3.87 vs 4.88 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
3.82 vs 5.22 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
3.83 vs 5.83 IR CD-LD hours @ 1wk
NCT00869791 · Phase 2 · registry result, not featured evidence
On" Time Without Troublesome Dyskinesia 11.84 vs 10.91 IR CD-LD hours @ 22wk
absolute value · hours
NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3
show 1 more result
11.36 vs 9.98 CLE hours @ 2wk
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS II III Sum -14.9 vs -0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-12.9 vs -0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-11.7 vs -0.6 placebo score @ 30wk145mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PDQ-39 -6 vs 0.6 placebo score @ 30wk390 mg LD
absolute change · score
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-3.8 vs 0.6 placebo score @ 30wk245 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
-4.4 vs 0.6 placebo score @ 30wk145 mg LD
NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3
PGIC 5.2 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.4 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.3 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
CGI-C 5.5 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 2 more results
5.7 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
5.6 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
PDQ-8 9.6 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01411137 · Phase 3 · registry result, not featured evidence
show 3 more results
8.1 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
8.5 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
9 score @ 24wk
NCT01411137 · Phase 3 · registry result, not featured evidence
Awake OFF Time 23.98% (n=83) vs 32.48% (n=83) CLE @ 2wk
absolute value · percentage points
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 29.3 vs 31.7 CLE score @ 2wk
absolute change · score
NCT01130493 · Phase 3 · registry result, not featured evidence
UPDRS Parts II+III 26.4 score @ 39wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence
UPDRS Total 30.5 score @ 39wk
absolute value · score
Extension (open-label)
No placebo or comparator arm
NCT01096186 · Phase 3 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Levodopa-carbidopa intestinal gel's landscape · Rytary (IPX066)'s landscape